GlassScriptPhysician profile
Marc J Ullman
NPI 1619005832
$10,914.73
in general payments reported to CMS, 2019-2025
24 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $599 · 2021: $1,396 · 2022: $1,521 · 2023: $1,658 · 2024: $3,270 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600 · Travel and Lodging: $1,189 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.41 |
| Travel and Lodging | $1,189.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,877.56 | 2019-2025 | Precision 1, Dailies Total1, Dailies Aqua Comfort Plus |
| Bausch & Lomb Americas INC. | $966.00 | 2023-2025 | Miebo, Xiidra, Infuse |
| Oyster Point Pharma, INC. | $772.55 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $613.16 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $593.29 | 2024-2025 | Xdemvy |
| Allergan, INC. | $460.75 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $369.58 | 2020-2025 | Cequa |
| Dompe US, INC. | $180.78 | 2020-2025 | Oxervate |
| Abbvie INC. | $179.63 | 2022-2024 | Vuity, Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.59 | 2019-2021 | |
| Glaukos Corporation | $123.89 | 2022 | |
| Horizon Therapeutics Plc | $111.43 | 2023 | Tepezza |
| Astellas Pharma US INC | $111.33 | 2024 | Izervay |
| Notal Vision, INC. | $68.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $65.25 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $55.40 | 2019-2025 | Misight Contact Lens |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Eyevance Pharmaceuticals LLC | $36.71 | 2019-2021 | |
| Oasis Medical, INC. | $26.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $24.19 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $17.42 | 2023 | Acuvue |
| Menicon America INC | $17.34 | 2020 | |
| Sight Sciences, INC. | $13.94 | 2023 | Tearcare System |
| Lkc Technologies, INC. | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Ullman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.